Avista Capital Partners Mergers and Acquisitions Summary

Private Equity Firm Profile

In the last 3 years, Avista Capital Partners has acquired 8 companies. It has also invested in 1 other.

Avista Capital Partners’ most common sectors for investment arelife science (25%) and medical products (16%) . The Firm’s most common investment types include secondary buyout (33%) and buyout (lbo, mbo, mbi) (31%). In total, Avista Capital Partners has invested in 18 US states and 8 different countries. Its largest (disclosed) acquisition occurred in 2008 when it acquired ConvaTec for $4.1B.

In the last 3 years, Avista Capital Partners has exited 3 companies. The Firm’s most common exit type is trade sale (50%). Avista Capital Partners’ largest (disclosed) exit occurred in 2011 when it sold Nycomed Pharma AG for $10.8B.

Join Mergr to view Avista Capital Partners’ full profile and discover more mega-sized private equity firm investors just like it.

M&A Summary

  • M&A Total Activity82
    • M&A Buy Activity52
    • M&A Sell Activity30
  • Total Sectors Invested 20
  • Total Countries Invested 8
  • M&A Buy/Sell Connections 28
  • M&A Advisors 14

Avista Capital Partners

Avista Capital Holdings, LP

65 East 55th Street,18th Floor,
New York, New York 10022
United States
(212) 593-6900
www.avistacap.com
info@avistacap.com

Avista Capital Partners is a private investment firm formed by a group of professionals with roots from DLJ Merchant Banking Partners. Avista makes controlling and minority investments in US based energy, healthcare, and media companies with revenues greater than $25 million. Typical transactions include leverage buyouts, build-ups, and growth capital financings. Avista Capital was formed in 2005 and is based in New York City with an additional office in Houston, Texas.


Investment Criteria

Sectors of Interest: Automotive, Business Services, Communications, Distribution, Energy Services and Equipment, Engineering, Environmental, Financial Services, Healthcare Services, Life Science, Manufacturing, Marketing, Media, Medical Products, Oil/Gas Exploration, Publishing, Renewable Energy, Utilities

Target Transaction Types: Buyout (LBO, MBO, MBI), Consolidation, Growth Capital, Recapitalization, Secondary Buyout

Geographic Preferences: East US, Midwest US, South US, West US, Western Europe

Transaction Criteria Min Max
Target Revenue 25 -
Target EBITDA - -
Investment Size 50 300
Enterprise Value - -
values in millions of USD

M&A Summary

Buy vs Sell

Year ≤ '18 '19 '20 '21 '22 '23 T
Buy (2.0/yr) # 42 1 3 2 4 - 52
vol $6.9B $344M $7.3B
Sell (0.8/yr) # 26 1 - 2 1 - 30
vol $17.9B $402M $170M $18.5B
  82

Most Recent M&A

Company Date Value Type
Spear Education LLC 2022-12-19 - Secondary Buyout
Scottsdale, Arizona · www.speareducation.com
Taconic Biosciences, Inc. 2022-11-01 - Secondary Buyout
Hudson, New York · www.taconic.com
WellSpring Pharmaceutical Corp. 2022-08-23 - Secondary Buyout
Sarasota, Florida · www.wellspringpharm.com
Inform Diagnostics, Inc. 2022-04-18 170M USD Trade Sale
Irving, Texas · www.informdx.com
Probo Medical LLC 2022-02-15 - Secondary Buyout
Fishers, Indiana · www.probomedical.com
Acino International AG 2021-09-16 - Trade Sale
Zurich, Czech Republic · www.acino.swiss
Arcadia Consumer Healthcare, Inc. 2021-08-09 - Secondary Sale
Bridgewater, New Jersey · www.arcadiach.com
eMolecules, Inc. 2021-03-25 - Growth Capital
San Diego, California · www.emolecules.com
Cooper Consumer Health SAS 2021-03-12 - Secondary Buyout
Paris, France · www.cooperconsumerhealth.eu
Solmetex LLC 2020-12-17 - Secondary Buyout
Marlborough, Massachusetts · www.solmetex.com
View All >>

Portfolio M&A

Company Acquired Add-On/Sale Date #
WellSpring Pharmaceutical Corp. 2022-08-23 Bayer AG - Iconic OTC Skin Care Brands 2023-04-04 1
Sarasota, Florida · www.wellspringpharm.com Leverkusen, Germany
Probo Medical LLC 2022-02-15 Med Imaging Healthcare Ltd. 2022-08-15 5
Fishers, Indiana · www.probomedical.com Knowsley, United Kingdom · www.mihealthcare.co.uk
XIFIN, Inc. 2020-02-05 OmniSYS LLC 2021-12-14 2
San Diego, California · www.xifin.com Dallas, Texas · www.omnisys.com
Vision Healthcare N.V. 2020-06-01 NaturaMed Pharma AS 2020-12-21 4
Kortrijk, Belgium · www.visionhealthcare.eu Drammen, Netherlands · www.naturamed-pharma.no

M&A by Sector

Sector Current # Value All-time # Value
Life Science 5 (33%) - 13 (25%) 1.0B (14%)
Medical Products 2 (13%) - 8 (15%) 4.6B (64%)
Oil/Gas Exploration 1 (7%) - 5 (10%) 405M (6%)
Healthcare Services 1 (7%) - 4 (8%) 635M (9%)
Energy Services and Equipment - - 3 (6%) -
Consumer Products 1 (7%) 344M (100%) 2 (4%) 344M (5%)
Information Technology - - 2 (4%) 253M (3%)
Business Services 1 (7%) - 2 (4%) -
Communications - - 2 (4%) -
Apparel/Textiles - - 1 (2%) -
Automotive - - 1 (2%) -
Distribution - - 1 (2%) -
Education 1 (7%) - 1 (2%) -
Environmental - - 1 (2%) -
Internet Software and Services 1 (7%) - 1 (2%) -
Machinery 1 (7%) - 1 (2%) -
Manufacturing - - 1 (2%) -
Marketing - - 1 (2%) -
Publishing - - 1 (2%) -
Software 1 (7%) - 1 (2%) -
Total 15 $344M 52 $7.3B

Acquisitions By Geo

State/Country Current # Value All-time # Value
United States 13 (87%) - 43 (83%) 2.4B (33%)
  Texas - - 8 (15%) 405M (6%)
  California 3 (20%) - 6 (12%) -
  New Jersey 2 (13%) - 5 (10%) -
  Massachusetts 1 (7%) - 3 (6%) 525M (7%)
  Maryland 1 (7%) - 3 (6%) 210M (3%)
  Pennsylvania 1 (7%) - 3 (6%) -
  New York 1 (7%) - 3 (6%) -
  Minnesota - - 2 (4%) -
  Ohio 1 (7%) - 1 (2%) -
  Indiana 1 (7%) - 1 (2%) -
  Florida 1 (7%) - 1 (2%) -
  Arizona 1 (7%) - 1 (2%) -
  North Carolina - - 1 (2%) 600M (8%)
  Illinois - - 1 (2%) 253M (3%)
  District of Columbia - - 1 (2%) -
  Connecticut - - 1 (2%) -
  Colorado - - 1 (2%) -
United Kingdom - - 3 (6%) 4.1B (56%)
Belgium 1 (7%) 344M (100%) 1 (2%) 344M (5%)
France 1 (7%) - 1 (2%) -
Czech Republic - - 1 (2%) 414M (6%)
Denmark - - 1 (2%) -
Sweden - - 1 (2%) -
Switzerland - - 1 (2%) -
Domestic 13 (87%) - 43 (83%) 2.4B (33%)
Cross-border 2 (13%) 344M (100%) 9 (17%) 4.9B (67%)
Total 15 $344M 52 $7.3B

Acquisitions by Deal Type

Type Current # Value All-time # Value
Secondary Buyout 9 (60%) - 17 (33%) 600M (8%)
Buyout (LBO, MBO, MBI) 1 (7%) - 16 (31%) 350M (5%)
Divestiture 3 (20%) 344M (100%) 8 (15%) 5.6B (77%)
Growth Capital 1 (7%) - 5 (10%) -
Going Private - - 2 (4%) 667M (9%)
Stake Purchase - - 2 (4%) 55M (1%)
PIPE 1 (7%) - 2 (4%) -
Total 15 $344M 52 $7.3B

Exits by Deal Type

Type Total # Value
Trade Sale - Public Company 12 (40%) 18.3B (99%)
IPO 5 (17%) -
Secondary Sale 5 (17%) -
Trade Sale 4 (13%) 170M (1%)
Bankruptcy 1 (3%) -
Merger 1 (3%) -
Sold to Management 1 (3%) -
Unknown 1 (3%) -
Total 30 $18.5B

Top M&A Advisors

Financial Deals
Credit Suisse Investment Banking
 2
SunTrust Robinson Humphrey, Inc.
 1
J.P. Morgan Securities
 1
Legal Deals
Ropes & Gray
 7
Kirkland & Ellis
 5
Weil Gotshal & Manges LLP
 4

Deal Values

buy # Total
> $1B 1 $4.1B
$100M to $1B 8 $3.1B
< $100M 1 $55M
TOTAL $7.3B
Largest ConvaTec, Inc.
$4.1B (2008-08-02)
sell # Total
> $1B 4 $15.9B
$100M to $1B 7 $2.6B
TOTAL $18.5B
Largest Nycomed Pharma AG
$10.8B (2011-05-19)

M&A Connections

Deals
Acquired from
Investor(s)
33%
17 (33%)
Strategic(s)
12%
6 (12%)
Exited to
Investor(s)
17%
5 (17%)
Strategic(s)
53%
16 (53%)

Investor Summary

Investor Type

Private Equity Firm

Size

Mega

PE Assets

6.0B USD

Established

2005

Specialist/Generalist

Specialist

Leadership

Thompson Dean

Chairman and Co-Head of Avista’s Investment Committee

David Burgstahler

Co-founder & Managing Partner, Co-CEO

Amanda Heravi

Founding Member & Head of Investor Relations, Managing Director

John Cafasso

Managing Director & CFO

Ben Silbert

Managing Director & General Counsel

FAQ

When was Avista Capital Partners founded?

Avista Capital Partners was founded in 2005.

What type of investor is Avista Capital Partners?

Avista Capital Partners is a private equity firm.

Where is Avista Capital Partners headquartered?

Avista Capital Partners is headquartered in New York, New York.

How much capital does Avista Capital Partners have under management?

Avista Capital Partners has 6.0B USD under management.

 Subscribe to unlock this and 197,042
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More
1 Week Free Trial Learn More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB

Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.5K Private Equity Firms
  • 188K M&A Transactions
  • 193K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.5K M&A Advisors
    (Investment Banks and Law Firms)
  • 74K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.

Mergr

Product

Company

Legal